Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Cytotoxic effect of Eudragit L-100 nanoparticle-based cisplatin on lung cancer

Firas Falih Al-Mamoori^1,2 , Habibah A Wahab¹, Waqas Ahmad¹

¹School of Pharmaceutical Science, Universiti Sains Malaysia, Minden 11800, Malaysia; ²Department of Pharmaceutics, Pharmacy College, University of Babylon, Iraq.

For correspondence:- Firas Al-Mamoori Email: ferasfalih@student.usm.my Tel:+964-78025212336

Received: 19 March 2024 Accepted: 2 October 2024 Published: 29 October 2024

Citation: Al-Mamoori FF, Wahab HA, Ahmad W. Cytotoxic effect of Eudragit L-100 nanoparticle-based cisplatin on lung cancer. Trop J Pharm Res 2024; 23(10):1591-1598 doi: 10.4314/tjpr.v23i10.1

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop Eudragit L-100 nanoparticle-based cisplatin (Cis) and determine its cytotoxicity effect against lung cancer. Methods: Eudragit L-100 nanoparticles (NPs) were prepared using the double-emulsion solvent evaporation method. Morphology, size, polydispersity index, zeta potential, drug encapsulation efficiency, and in vitro drug release in phosphate-buffered saline (pH 7.4) were investigated. Results: Cis-loaded NPs' cytotoxicity was higher than free drugs against lung cancer cells (p < 0.05). Moreover, cis-loaded nanocarriers inhibited NCI-H60 lung carcinoma cells using the MTT assay in a dose-dependent manner. Conclusion: Eudragit L-100 NPs-based cisplatin exhibits a promising carrier system for effectively delivering chemotherapeutic agents targeting lung cancer. Further studies should focus on optimizing formulation parameters, conducting comprehensive pharmacokinetic and mechanistic studies, and evaluating therapeutic efficacy and safety in preclinical models.

Keywords: Cisplatin, Controlled delivery, Lung cancer, Eudragit L-100 nanoparticles, Cytotoxic